Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
An Audio Webinar
By NIHCM
Transforming Health Care Through Evidence and Collaboration
An estimated 2.1 million Americans have an opioid use disorder, according to the latest national data. Opioid overdose takes the lives of 4.6 Americans every hour. With a crisis of this magnitude, it is easy to lose sight of the fact that effective, life-saving treatments are out there. Medication-assisted therapy and the opioid-reversing drug naloxone, for example, are two highly effective interventions for addiction and overdose, but access barriers persist.
In this part of our opioid webinar series, we explored ways to expand the use of evidence-based treatment, including:
- Strategies to smooth access to key drug therapies through standing orders to dispense and removal of prior authorization requirements
- Federal and private-sector initiatives to protect the patients from sub-standard or fraudulent addiction treatment
- A multi-sector collaboration to adopt principles of care for substance abuse treatment and to help practitioners stay abreast of the evidence
- Ideas for using pharmacy data to identify potential abuse and for deploying telehealth technology to improve access to treatment
***
Share this:
Filed under: Drugs and Pharma, Videos | Tagged: NIHCM Foundation, OPIOID CRISIS? |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Opioid Addiction Among the Employer-Insured Cost $2.6 Billion in 2016
Kaiser Family Foundation recently released an issue brief on opioid use among those with employer coverage. Here are some key findings from the report:
• 37% of people addicted to opioids in 2016 were covered by private health insurance.
• Opioid addiction among those with employer coverage cost $2.6 billion in 2016.
• 17.3% of large employer plan enrollees had at least one opioid prescription in 2009.
• The highest opioid use by age group was 22% for ages 55-64 in 2016.
• 15% of women with employer coverage have an opioid prescription, vs 12% of men.
• Opioid use among people with large employer coverage is highest in the South (16%).
Source: Kaiser Family Foundation, April 5, 2018
LikeLike
56% of Adults With Opioid Addiction Were Employed in 2016
Kaiser Family Foundation recently released a brief on the opioid epidemic and Medicaid. Here are some key findings from the report:
• In 2016, 1.9 million nonelderly adults in the United States had an opioid addiction.
• Medicaid covers 4 in 10 nonelderly adults with opioid addiction.
• In 2016, nearly 6 in 10 (56%) of adults with opioid addiction were employed.
• 3 in 4 nonelderly adults with opioid addiction were white in 2016.
• 58% of adults with opioid addiction were male and 48% were ages 18-34.
Source: Kaiser Family Foundation, April 11, 2018
LikeLike
FDA Nearing Approval of Highly Addictive New Opioid
DSUVIA, the drug in question, is a form of Sufentanil—which is more potent than fentanyl and morphine. It would be sold as an under-the-tongue tablet. While it can treat pain, it’s associated with a high risk for addiction and being dependent upon it.
Side effects include but aren’t limited to restlessness, muscle spasms, chest pain and fast heartbeat, according to PubMed Health.
http://www.msn.com/en-us/news/us/fda-nearing-approval-of-highly-addictive-new-opioid/ar-BBOErl0?li=BBnbfcL
Ann Miller RN MHA
LikeLike